WallStSmart

Crown Castle (CCI)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Crown Castle generates 61671% more annual revenue ($4.21B vs $6.82M). CCI leads profitability with a 25.1% profit margin vs -40.7%. CCI earns a higher WallStSmart Score of 49/100 (D+).

CCI

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 7.0Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: -0.67

EUDA

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -47.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCISignificantly Overvalued (-29.8%)

Margin of Safety

-29.8%

Fair Value

$66.29

Current Price

$94.49

$28.20 premium

UndervaluedFair: $66.29Overvalued

Intrinsic value data unavailable for EUDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCI3 strengths · Avg: 9.7/10
Operating MarginProfitability
47.7%10/10

Strong operational efficiency at 47.7%

Debt/EquityHealth
-12.8610/10

Conservative balance sheet, low leverage

Profit MarginProfitability
25.1%9/10

Keeps 25 of every $100 in revenue as profit

EUDA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.9%10/10

Revenue surging 78.9% year-over-year

Debt/EquityHealth
-0.5610/10

Conservative balance sheet, low leverage

Areas to Watch

CCI4 concerns · Avg: 2.8/10
P/E RatioValuation
38.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-206.7%2/10

ROE of -206.7% — below average capital efficiency

Revenue GrowthGrowth
-4.8%2/10

Revenue declined 4.8%

EUDA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$48.09M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-2.53M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CCI

The strongest argument for CCI centers on Operating Margin, Debt/Equity, Profit Margin. Profitability is solid with margins at 25.1% and operating margin at 47.7%.

Bull Case : EUDA

The strongest argument for EUDA centers on Revenue Growth, Debt/Equity. Revenue growth of 78.9% demonstrates continued momentum.

Bear Case : CCI

The primary concerns for CCI are P/E Ratio, Piotroski F-Score, Return on Equity.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

CCI profiles as a declining stock while EUDA is a hypergrowth play — different risk/reward profiles.

CCI carries more volatility with a beta of 0.95 — expect wider price swings.

EUDA is growing revenue faster at 78.9% — sustainability is the question.

CCI generates stronger free cash flow (452M), providing more financial flexibility.

Bottom Line

CCI scores higher overall (49/100 vs 24/100), backed by strong 25.1% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Crown Castle

REAL ESTATE · REIT - SPECIALTY · USA

Crown Castle is a real estate investment trust and provider of shared communications infrastructure in the United States. Its network includes over 40,000 cell towers and nearly 80,000 route miles of fiber supporting small cells and fiber solutions. Headquartered in Houston, Texas, the company has 100 offices nationwide.

Visit Website →

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical innovator dedicated to the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. The company utilizes cutting-edge technologies and maintains a strong clinical pipeline, emphasizing supportive care and immune modulation. With a deep commitment to research and development, EUDA is strategically positioned to drive healthcare advancements, improve patient outcomes, and broaden access to vital medical treatments.

Visit Website →

Want to dig deeper into these stocks?